Core Viewpoint - The resignation of Gong Dexiong as Chairman and Executive Director of Dongfang Securities is attributed to work relocation, and he will no longer hold any positions within the company or its subsidiaries [1] Group 1: Leadership Changes - Gong Dexiong has served in various roles including Party Secretary, Executive Director, and Chairman since September 2023 [3] - Following Gong's resignation, Vice Chairman Lu Weiming will assume related responsibilities until a new chairman is appointed [4] Group 2: Strategic Vision and Performance - During his tenure, Gong Dexiong emphasized a vision to build a competitive and influential modern investment bank, proposing a "three-step" medium to long-term strategic roadmap [3] - Under Gong's leadership, Dongfang Securities reported a steady performance increase, with 2024 projected revenues of 19.19 billion and net profits of 3.35 billion, reflecting year-on-year growth of 12.29% and 21.66% respectively [3] - For the first three quarters of the current year, the company achieved revenues of 12.71 billion and net profits of 5.11 billion, marking significant year-on-year increases of 39.38% and 54.76% [3]

12月8日晚间，东方证券董事长龚德雄辞职，由副董事长鲁伟铭代为履行董事长职责。 董事长龚德雄辞职 12月8日，东方证券公告，公司于近日收到龚德雄的辞职报告。因工作调动原因，龚德雄先生申请辞去公司董 事长、执行董事和董事会战略与可持续发展委员会主任委员、薪酬与提名委员会委员等职务，辞职后不再担任 公司及控股子公司任何职务。 龚德雄的卸任早有端倪。 根据此前上海发布11月14日的消息，东方证券党委书记、董事长龚德雄拟提名任市 管企业经理班子正职。而最新公告显示，龚德雄的原定任期到期日为2027年11月21日，正式离任日期为2025年 12月8日。 东方证券公告称，龚德雄自2023年9月起，先后任职公司党委书记、执行董事、董事长等职，始终恪守金融报 国初心，践行金融为民使命，围绕建设具有国内竞争力和国际影响力的一流现代投资银行的公司愿景，提 出"三步走"中长期战略路线图，主导制定和推动实施公司2025—2027年战略规划。 公告还提到，龚德雄坚持和加强党的全面领导，坚持全面深化改革，围绕"数字化、集团化、国际化"的战略方 向，聚焦大财富、大投行两大重点领域，推动公司锻造综合化客群经营、数字化科技驱动、内生性合规风控 ...

Core Insights - The chairman of Dongfang Securities, Gong Dexiong, has officially resigned, with Vice Chairman Lu Weiming taking over the responsibilities [1][5][12] - Under Gong's leadership, Dongfang Securities has seen significant performance improvements, achieving a revenue of 12.708 billion yuan, a year-on-year increase of 39.38%, and a net profit of 5.110 billion yuan, up 54.76% [1][7] Group 1: Leadership Transition - Gong Dexiong's tenure as chairman lasted nearly three years, during which he was instrumental in the company's strategic direction and financial recovery [1][2] - Lu Weiming, the new acting chairman, is expected to continue the established strategic framework focusing on "big wealth, big investment banking, and big institutions" [6][12] Group 2: Strategic Achievements - Gong Dexiong's leadership marked a significant period for Dongfang Securities, with a clear strategic path set for 2025-2027, emphasizing the development of a first-class modern investment bank [2][8] - The company has excelled in investment banking, particularly in areas like technology innovation and green finance, enhancing its market reputation and share [3][9] Group 3: Financial Performance - Dongfang Securities has consistently ranked among the top in the industry for key financial metrics, including asset scale, revenue, and net profit, with a strong return on equity (ROE) [2][4] - The company has maintained a robust risk management capability and has received the highest regulatory ratings for several consecutive years [2][4] Group 4: Institutional and Wealth Management - The institutional business has become a crucial pillar for Dongfang Securities, with a strong focus on providing high-quality decision support to institutional clients [4][10] - The wealth management division has undergone a transformation towards a client-centric model, enhancing service efficiency and product offerings [3][9] Group 5: Corporate Social Responsibility - Under Gong's leadership, the company has placed a strong emphasis on corporate culture and social responsibility, actively participating in initiatives like rural revitalization and investor education [11]

（ 於 中 華 人 民 共 和 國 註 冊 成 立 之 股 份 有 限 公 司 ，中 文 公 司 名 稱 為 「東 方 証 券 股 份 有 限 公 司 」， 在 香 港 以「 東 方 證 券」（中 文 ）及「DFZQ」（ 英 文 ） 開 展 業 務 ） （股份代號：03958） 董事名單與其角色和職能 非執行董事 劉煒先生 楊波先生 石磊先生 李芸女士 徐永淼先生 任志祥先生 孫維東先生 （職工董事） 獨立非執行董事 吳弘先生 馮興東先生 羅新宇先生 陳漢先生 朱凱先生 1 董事會下設四個委員會。下表提供各董事會成員所屬委員會中所擔任職務之信息： | | 董事委員會 | 戰略與 | 合規與風險 | | 薪酬與提名 | | --- | --- | --- | --- | --- | --- | | | | 可持續發展 | 管理委員會 | 審計委員會 | 委員會 | | 董事 | | 委員會 | | | | | 魯偉銘先生 | | M | C | | | | 盧大印先生 | | M | | | | | 劉煒先生 | | | | M | | | 楊波先生 | | M | | | | | 石磊先生 | | | | M ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：中国基金报 记者 孙越 【导读】东方证券董事长龚德雄因工作调动辞职，副董事长鲁伟铭暂代为履行职责 东方证券迎来重大人事变动。 12月8日，东方证券发布公告称，公司于近日收到龚德雄的辞职报告。龚德雄因工作调动，申请辞去公 司董事长、执行董事和董事会战略与可持续发展委员会主任委员、薪酬与提名委员会委员等职务，辞职 后不再担任公司及控股子公司任何职务。 在新任董事长任职前，东方证券副董事长鲁伟铭将代为履行董事长、法定代表人及香港联交所授权代表 职责。 | 姓名 | 离任职务 | 离任时间 | 原定任期 | 离任原因 | 是否第 续在上 市公司 | 是否存 在未履 行完毕 | | --- | --- | --- | --- | --- | --- | --- | | | | | 到期日 | | 及其控 | 的公开 | | | | | | | 股子公 | 承该 | | | | | | | 司任职 | | | | 董事长、执 | | | | | | | | 行童事、战 | | | | | | | | 略与可持 | | | | | | | | ...

根据《公司章程》等规定，在新任董事长任职前，由公司副董事长鲁伟铭先生代为履行董事长、法定代 表人及香港联交所授权代表(就《香港联合交易所有限公司证券上市规则》第3.05条而言)职责。 智通财经APP讯，东方证券(03958)发布公告，于2025年12月8日收到公司董事长龚德雄先生提交的书面 辞职报告，龚德雄先生因工作调动原因提出辞去公司董事长、执行董事、法定代表人及香港联合交易所 有限公司授权代表(就《香港联合交易所有限公司证券上市规则》第3.05条而言)等职务，同时一并辞去 董事会战略与可持续发展委员会主任委员职务及薪酬与提名委员会委员职务，其辞职之后将不再担任公 司及控股子公司任何职务。 ...

【导读】 东方证券董事长龚德雄因工作调动辞职，副董事长鲁伟铭暂代为履行职责 中国基金报记者 孙越 东方证券迎来重大人事变动。 12月8日，东方证券发布公告称，公司于近日收到龚德雄的辞职报告。龚德雄因工作调动，申 请辞去公司董事长、执行董事和董事会战略与可持续发展委员会主任委员、薪酬与提名委员 会委员等职务，辞职后不再担任公司及控股子公司任何职务。 在新任董事长任职前，东方证券副董事长鲁伟铭将代为履行董事长、法定代表人及香港联交 所授权代表职责。 证券代码:600958 证券简称:东方证券 公告编号:2025-053 关于公司董事长离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 一、董事长提前离任的基本情况 东方证券股份有限公司(以下简称"公司")于近日收到龚德雄 先生的辞职报告。因工作调动原因,龚德雄先生申请辞去公司董事长、 执行董事和董事会战略与可持续发展委员会主任委员、薪酬与提名委 员会委员等职务,辞职后不再担任公司及控股子公司任何职务。 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或 任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 之 股 份 有 限 公 司 ，中 文 公 司 名 稱 為 「東 方 証 券 股 份 有 限 公 司 」， 在 香 港 以「 東 方 證 券」（中 文 ）及「DFZQ」（ 英 文 ） 開 展 業 務 ） （股份代號：03958） 董事長辭任 東方證券股份有限公司（「公司」）董事會（「董事會」）於 2025年 12月 8日收到公司董事 長龔德雄先生提交的書面辭職報告，龔德雄先生因工作調動原因提出辭去公司董 事長、執行董事、法定代表人及香港聯合交易所有限公司（「香港聯交所」）授權代表 （就《香港聯合交易所有限公司證券上市規則》第 3.05條而言）等職務，同時一併辭去 董事會戰略與可持續發展委員會主任委員職務及薪酬與提名委員會委員職務，其辭 職之後將不再擔任公司及控股子公司任何職務。龔德雄先生向董事會確認，其與公 司及董事會並無任何意見分歧，亦無有關其辭任而須 ...

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

北京商报讯（记者 李海媛）12月8日，东方证券公告称，于近日收到龚德雄的辞职报告。因工作调动原 因，龚德雄申请辞去公司董事长、执行董事和董事会战略与可持续发展委员会主任委员、薪酬与提名委 员会委员等职务，辞职后不再担任公司及控股子公司任何职务。 东方证券表示，根据公司《章程》等规定，在新任董事长任职前，由公司副董事长鲁伟铭代为履行董事 长、法定代表人及香港联交所授权代表职责。 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 | 是否继 续在上 市公司 及其控 | 是否存 在未展 行完毕 的公开 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 股子公 | | | | | | | | 司任职 | 承诺 | | 黄德雄 | 董事长、执 行重事、战 略与可持 续发展委 员会主任 | 2025 年 12 月8日 | 2027年11 月 21 日 | | | | | | | | | 工作调动 | 否 | 否 | | | 委员、新酬 | | | | | | | | 与提名委 | | | | | | | | 员会委员 | | | | ...